Search This Blog

Friday, June 28, 2019

FDA OKs Pfizer’s Avastin biosimilar

The FDA approves Pfizer’s (NYSE:PFE) Zirabev (bevacizumab-bvzr), its biosimilar to Roche’s (OTCQX:RHHBY) cancer med Avastin.
Shares are up 1% premarket on light volume.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)